First description of antimicrobial resistance in carbapenem-susceptible Klebsiella pneumoniae after imipenem treatment, driven by outer membrane remodeling.

BMC Microbiology
Xuebin TianTieli Zhou

Abstract

The emergence of carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a looming threat to human health. Although there are numerous studies regarding porin alteration in association with the production of ESBLs and/or AmpC β-lactamase, a systematic study on the treatment-emergence of porins alteration in antibiotic resistance does not yet exist. The aim of this study was to investigate the underlying mechanism of resistance of K. pneumoniae during carbapenem treatment. Here, we report three strains (FK-2624, FK-2723 and FK-2820) isolated from one patient before and after imipenem treatment during hospitalization. Antibiotic susceptibility testing indicated that that the first isolate, FK-2624, was susceptible to almost all tested antimicrobials, being resistant only to fosfomycin. The subsequent isolates FK-2723 and FK-2820 were multidrug resistant (MDR). After imipenem therapy, FK-2820 was found to be carbapenem-resistant. PCR and Genome Sequencing analysis indicated that oqxA, and fosA5, were identified in all three strains. In addition, FK-2624 also harbored blaSHV-187 and blaTEM-116. The blaSHV-187 and blaTEM-116 genes were not detected in FK-2723 and FK-2820. blaDHA-1, qnrB4, aac (6')-IIc, and blaSHV-12, EreA2, CatA2, S...Continue Reading

References

Jul 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·G NilssonA von Gabain
Mar 5, 2003·The Journal of Antimicrobial Chemotherapy·Ellen Smith MolandKenneth S Thomson
Aug 5, 2005·Biological & Pharmaceutical Bulletin·Wakano OgawaTomofusa Tsuchiya
Aug 6, 2005·Journal of Clinical Microbiology·Laure DiancourtSylvain Brisse
Jan 5, 2006·Applied Microbiology and Biotechnology·S Jana, J K Deb
Jan 24, 2007·Bioinformatics·Arthur L DelcherSteven L Salzberg
Dec 25, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·L DrieuxV Jarlier
Apr 24, 2009·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·A BeltrameW Arcese
Jul 10, 2012·The Journal of Antimicrobial Chemotherapy·Benoît DoubletMichael R Mulvey
Mar 20, 2014·Bioinformatics·Torsten Seemann
Oct 3, 2014·Journal of Clinical Microbiology·Fabrice CompainDominique Decré
Dec 30, 2014·Journal of Microbiological Methods·Zanzan LiuQingge Li
Mar 27, 2015·Bioinformatics·Emanuele BosiMarco Fondi
Jul 23, 2015·Bioinformatics·Andrew J PageJulian Parkhill
Feb 4, 2016·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Angeliki MavroidiEvangelia D Platsouka
Jun 28, 2016·Nucleic Acids Research·Tatiana TatusovaJames Ostell
Apr 15, 2018·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Min HaoMinggui Wang
May 17, 2019·Clinical Microbiology Reviews·Thomas A Russo, Candace M Marr

❮ Previous
Next ❯

Datasets Mentioned

BETA
CP040697.1
FK-2820
CP000647

Methods Mentioned

BETA
PCR
electrophoresis

Software Mentioned

SOAP denovo
Roary
RaxML
MagiBlast
Bowtie2
MLST
Kleborate
MeDuSa
MAUVE
Quantity One

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.